Animal models for motor neuron disease

Laboratory Animal Science

Volumn 49, Issue 5, 1999, Pages 480-487

  Green, Sherril L ^a   Tolwani, Ravi J ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Building 330 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL MODEL; DOG; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; GENETIC ENGINEERING; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HORSE; MOTOR NEURON DISEASE; MOUSE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SURVIVAL TIME; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; DOGS; GENETIC ENGINEERING; HORSES; HUMANS; MICE; MOTOR NEURON DISEASE;

EID: 0032758596     PISSN: 00236764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Mitsumoto, H. 1994. Classification and clinical features of amyotrophic lateral sclerosis. In Amyotrophic lateral sclerosis. A comprehensive guide to management. Demos Publications, New York.
2. Hirano, A. 1996. Neuropathology of ALS: an overview. Neurology 47:S63-S66.
3. Charcot, J. M., and A. Joffroy. 1869. Deux cas d'atrophie musculaire progressive avec les lésions de la substance grise et faisceaux antérolatéraux de la moelle épinière. Arch. Physiol. Norm. Pathol. 2:354-367, 629-649, 744-760.
4. Price, D. L., D. W. Cleveland, and V. E. Koliatsos. 1994. Motor neuron disease and animal models. Neurobiol. Dis. 1:3-11.
5. Tandan, R., and W. G. Bradley. 1985. Amyotrophic lateral sclerosis: part 1. Clinical features, pathology, and ethical issues in management. Ann. Neurol. 18:271-280.
6. Tandan, R., and W. G. Bradley. 1985. Amyotrophic lateral sclerosis: part 2. Etiopathogenesis. Ann. Neurol. 18:419-431.
7. Emery, A. E., and S. Holloway. 1982. Familial motor neuron diseases. Adv. Neurol. 36:139-147.
8. Siddique, T., M. A. Pericak-Vance, B. R. Brooks, et al. 1989. Linkage analysis in familial amyotrophic lateral sclerosis. Neurology 39:919-925.
9. Rosen, D. R., T. Siddique, D. Patterson, et al. 1993. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59-62.
10. Bruijn, L. I., M. K. Houseweart, S. Kato, et al. 1998. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281: 1851-1854.
11. Sies, H., W. Stahl, and A. R. Sundquist. 1992. Antioxidant functions of vitamins. Vitamins E and C, beta-carotene, and other carotenoids. Ann. N. Y. Acad. Sci. 669:7-20.
12. Sillevis, S. P., and J. M. de Jong. 1989. Animal models of amyotrophic lateral sclerosis and the spinal muscular atrophies. J. Neurol. Sci. 91:231-258.
13. Messer, A. 1994. Mutant mouse models of ALS. Neurobiol. Aging 15:247-248.
14. Price, D. L., V. E. Koliatsos, P. C. Wong, et al. 1996. Motor neuron disease and model systems: aetiologies, mechanisms and therapies. CIBA Found. Symp. 196:3-13.
15. Ludolph, A. C., and P. S. Spencer. 1996. Toxic models of upper motor neuron disease. J. Neurol. Sci. 139(Suppl.):53-59.
16. Pioro, E. P., and H. Mitsumoto. 1995. Animal models of ALS. Clin. Neurosci. 3:375-385.
17. Mitsumoto, H., and E. P. Pioro. 1995. Animal models of amyotrophic lateral sclerosis. Adv. Neurol. 68:73-87.
18. Ludolph, A. C. 1996. Animal models for motor neuron diseases: research directions. Neurology 47:S228-S232.
19. Cork, L. C., J. C. Troncoso, G. G. Klavano, et al. 1988. Neurofilamentous abnormalities in motor neurons in spontaneously occurring animal disorders. J. Neuropathol. Exp. Neurol. 47:420-431.
20. Tu, P. H., M. E. Gurney, J. P. Julien, et al. 1997. Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease. Lab. Invest. 76:441-456.
21. Gurney, M. E., H. Pu, A. Y. Chiu, et al. 1994. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264:1772-1775.
22. Ripps, M. E., G. W. Huntley, P. R. Hof, et al. 1995. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 92:689-693.
23. Wong, P. C., C. A. Pardo, D. R. Borchelt, et al. 1995. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14:1105-1116.
24. Gurney, M. E. 1997. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J. Neurol. Sci. 152(Suppl. 1):S67-S73.
25. Gurney, M. E. 1997. Transgenic animal models of familial amyotrophic lateral sclerosis. J. Neurol. 244(Suppl. 2): S15-S20.
26. Bowling, A. C., J. B. Schulz, R. H. J. Brown, et al. 1993. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J. Neurochem. 61:2322-2325.
27. Deng, H. X., A. Hentati, J. A. Tainer, et al. 1993. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 261:1047-1051.
28. Gurney, M. E., F. B. Cutting, P. Zhai, et al. 1996. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 39: 147-157.
29. Bensimon, G., L. Lacomblez, and V. Meininger. 1994. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 330:585-591.
30. Xu, Z., L. C. Cork, J. W. Griffin, et al. 1993. Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease. Cell 73:23-33.
31. Cote, F., J. F. Collard, and J. P. Julien. 1993. Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell 73:35-46.
32. Vechio, J. D., L. I. Bruyn, Z. Xu, et al. 1996. Sequence variants in human neurofilament proteins: absence of linkage to familial amyotrophic lateral sclerosis. Ann. Neurol. 40:603-610.
33. Meyer, M. A., and N. T. Potter. 1995. Sporadic ALS and chromosome 22: evidence for a possible neurofilament gene defect. Muscle Nerve 18:536-539.
34. Jones, J. M., R. L. Albin, E. L. Feldman, et al. 1993. mnd2: a new mouse model of inherited motor neuron disease. Genomics 16:669-677.
35. Klein, R. 1994. Role of neurotrophins in mouse neuronal development. FASEB J. 8:738-744.
36. Klein, R., R. J. Smeyne, W. Wurst, et al. 1993. Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal death. Cell 75:113-122.
37. Davies, A. M. 1994. Neurobiology. Tracking neurotrophin function. Nature 368:193-194.
38. Masu, Y., E. Wolf, B. Holtmann, et al. 1993. Disruption of the CNTF gene results in motor neuron degeneration. Nature 365:27-32.
39. Aguzzi, A., S. Brandner, S. Marino, et al. 1996. Transgenic and knockout mice in the study of neurodegenerative diseases. J. Mol. Med. 74:111-126.
40. Messer, A., N. L. Strominger, and J. E. Mazurkiewicz. 1987. Histopathology of the late-onset motor neuron degeneration (Mnd) mutant in the mouse. J. Neurogenet. 4:201-213.
41. Messer, A., and L. Flaherty. 1986. Autosomal dominance in a late-onset motor neuron disease in the mouse. J. Neurogenet. 3:345-355.
42. Mitsumoto, H., and W. G. Bradley. 1982. Murine motor neuron disease (the wobbler mouse): degeneration and regeneration of the lower motor neuron. Brain 105(Pt. 4): 811-834.
43. Shultz, L. D., H. O. Sweet, M. T. Davisson, et al. 1982. 'Wasted', a new mutant of the mouse with abnormalities characteristic to ataxia telangiectasia. Nature 297:402-404.
44. Schmalbruch, H., H. J. Jensen, M. Bjaerg, et al. 1991. A new mouse mutant with progressive motor neuronopathy. J. Neuropathol. Exp. Neurol. 50:192-204.
45. Pardo, C. A., B. A. Rabin, D. N. Palmer, et al. 1994. Accumulation of the adenosine triphosphate synthase subunit C in the mnd mutant mouse. A model for neuronal ceroid lipofuscinosis. Am. J. Pathol. 144:829-835.
46. Faust, J. R., J. S. Rodman, P. F. Daniel, et al. 1994. Two related proteolipids and dolichol-linked oligosaccharides accumulate in motor neuron degeneration mice (mnd/mnd), a model for neuronal ceroid lipofuscinosis. J. Biol. Chem. 269:10150-10155.
47. Bronson, R. T., B. D. Lake, S. Cook, et al. 1993. Motor neuron degeneration of mice is a model of neuronal ceroid lipofuscinosis (Batten's disease). Ann. Neurol. 33:381-385.
48. Bermingham, N. A., J. E. Martin, and E. M. Fisher. 1996. The mouse lysosomal membrane protein 1 gene as a candidate for the motor neuron degeneration (mnd) locus. Genomics 32:266-271.
49. Falconer, D. S. 1956. Wobbler (WR). Mouse News 15:23.
50. Krieger, C., T. L. Perry, S. Hansen, et al. 1991. The wobbler mouse: amino acid contents in brain and spinal cord. Brain Res. 551:142-144.
51. Tomiyama, M., K. Kannari, J. Nunomura, et al. 1994. Quantitative autoradiographic distribution of glutamate receptors in the cervical segment of the spinal cord of the wobbler mouse. Brain Res. 650:353-357.
52. Kaupmann, K., D. Simon-Chazottes, J. L. Guenet, et al. 1992. Wobbler, a mutation affecting motoneuron survival and gonadal functions in the mouse, maps to proximal chromosome 11. Genomics 13:39-43.
53. Wichmann, H., H. Jockusch, J. L. Guenet, et al. 1992. The mouse homolog to the ras-related yeast gene YPT1 maps on chromosome 11 close to the wobbler (WR) locus. Mamm. Genome 3:467-468.
54. Lutsep, H. L., and M. Rodriguez. 1989. Ultrastructural, morphometric, and immunocytochemical study of anterior horn cells in mice with "wasted" mutation. J. Neuropathol. Exp. Neurol. 48:519-533.
55. Padilla, M., C. Libertin, C. Krco, et al. 1990. Radiation sensitivity of T-lymphocytes from immunodeficient "wasted" mice. Cell. Immunol. 130:186-194.
56. Chambers, D. M., J. Peters, and C. M. Abbott. 1998. The lethal mutation of the mouse wasted (wst) is a deletion that abolishes expression of a tissue-specific isoform of translation elongation factor 1alpha, encoded by the Eef1a2 gene. Proc. Natl. Acad. Sci. USA 95:4463-4468.
57. Brunialti, A. L., C. Poirier, H. Schmalbruch, et al. 1995. The mouse mutation progressive motor neuronopathy (pmn) maps to chromosome 13. Genomics 29:131-135.
58. 1997. Mutant mice and neuroscience: recommendations concerning genetic background. Banbury Conference on Genetic Background in Mice. Neuron 19:755-759.
59. Sendtner, M., H. Schmalbruch, K. A. Stockli, et al. 1992. Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature 358:502-504.
60. Haase, G., P. Kennel, B. Pettmann, et al. 1997. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. Nat. Med. 3:429-436.
61. Sagot, Y., S. A. Tan, J. P. Hammang, et al. 1996. GDNF slows loss of motoneurons but not axonal degeneration or premature death of pmn/pmn mice. J. Neurosci. 16:2335-2341.
62. Mitsumoto, H., K. Ikeda, T. Holmlund, et al. 1994. The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann. Neurol. 36: 142-148.
63. Sendtner, M. 1997. Gene therapy for motor neuron disease. Nat. Med. 3:380-381.
64. Cork, L. C., J. W. Griffin, J. F. Munnell, et al. 1979. Hereditary canine spinal muscular atrophy. J. Neuropathol. Exp. Neurol. 38:209-221.
65. Lorenz, M. D., L. C. Cork, J. W. Griffin, et al. 1979. Hereditary spinal muscular atrophy in Brittany spaniels: clinical manifestations. J. Am. Vet. Med. Assoc. 175:833-839.
66. Sack, G. H. J., L. C. Cork, J. M. Morris, et al. 1984. Autosomal dominant inheritance of hereditary canine spinal muscular atrophy. Ann. Neurol. 15:369-373.
67. Blazej, R. G., C. S. Mellersh, L. C. Cork, et al. 1998. Hereditary canine spinal muscular atrophy is phenotypically similar but molecularly distinct from human spinal muscular atrophy. J. Hered. 89:531-537.
68. Mellersh, C. S., A. A. Langston, G. M. Acland, et al. 1997. A linkage map of the canine genome. Genomics 46:326-336.
69. Cork, L. C., D. L. Price, J. W. Griffin, et al. 1990. Hereditary canine spinal muscular atrophy: canine motor neuron disease. Can. J. Vet. Res. 54:77-82.
70. Pinter, M. J., R. F. Waldeck, N. Wallace, et al. 1995. Motor unit behavior in canine motor neuron disease. J. Neurosci. 15:3447-3457.
71. Ostrander, E. A., and E. Giniger. 1997. Semper fidelis: what man's best friend can teach us about human biology and disease. Am. J. Hum. Genet. 61:475-480.
72. Cummings, J. F., A. de Lahunta, C. George, et al. 1990. Equine motor neuron disease: a preliminary report. Cornell Vet. 80:357-379.
73. Divers, T. J., H. O. Mohammed, J. F. Cummings, et al. 1994. Equine motor neuron disease: findings in 28 horses and proposal of a pathophysiological mechanism for the disease. Equine Vet. J. 26:409-415.
74. Divers, T. J., H. O. Mohammed, and J. F. Cummings. 1997. Equine motor neuron disease. Vet. Clin. North Am.: Equine Pract. 13:97-105.
75. Cummings, J. F., A. de Lahunta, H. O. Mohammed, et al. 1995. Endothelial lipopigment as an indicator of alpha-tocopherol deficiency in two equine neurodegenerative diseases. Acta Neuropathol. (Berlin) 90:266-272.
76. de la Rua-Domenech, R., M. Wiedmann, H. O. Mohammed, et al. 1996. Equine motor neuron disease is not linked to Cu/Zn superoxide dismutase mutations: sequence analysis of the equine Cu/Zn superoxide dismutase cDNA. Gene 178:83-88.
77. de la Rua-Domenech, R., H. O. Mohammed, J. F. Cummings, et al. 1997. Intrinsic, management, and nutritional factors associated with equine motor neuron disease. J. Am. Vet. Med. Assoc. 211:1261-1267.